news
-
4 February 2021Sequana Medical announces granting of key alfapump DSRŪ patents in U.S. and Europe
Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces the granting of key patents for the alfapump DSR (Direct Sodium Removal) programme in the U.S. and European Union.
U.S. patent number 10,898,631 B2 and EU patent number EP 3 612 246 B1 are both entitled “Direct sodium removal method, solution and apparatus to reduce fluid overload in heart failure patients” and cover the alfapump DSR and its method of operation. Specifically, it covers the use of a no or low sodium infusate that is administered to a patient’s peritoneal cavity to directly remove sodium, and thereby fluid from the body to alleviate fluid overload in heart failure patients with residual renal function.
Ian Crosbie, Chief Executive Officer at Sequana Medical, commented: “We are very pleased with the granting of these patents in our key territories, which we believe provides significant protection for our alfapump DSR programme. We are excited for the prospect of this breakthrough approach to the potential treatment of diuretic-resistant fluid overload in heart failure – an enormous burden on patients, clinicians and payers. The strong interim results from the RED DESERT study that we announced in October 2020 suggest that not only can alfapump DSR therapy potentially manage the fluid and sodium balance of these patients without the need of diuretics but also restore their diuretic responsiveness, enabling a gentler and more effective management of this enormous problem. Following these very promising data, we intend to explore the use of alfapump DSR therapy in fluid overload related to haemodialysis and pre-dialysis renal failure. We look forward to reporting the top-line data from the RED DESERT study in up to 10 patients by the end of H1 2021 and initiating SAHARA DESERT, our dose-ranging study of alfapump DSR in decompensated heart failure patients.”
Related
Sequana Medical announces H1 2020 results and provides business update
Sequana Medical announces €7.3 million debt financing and provides clinical update
Sequana Medical announces 2019 Full Year Results and 2020 Outlook
Sequana Medical announces new share capital amount and new number of shares
Sequana Medical announces 2019 Half Year Results and Year-to-date Business Update
Sequana Medical appoints leading experts as Heart Failure Scientific Advisors
Sequana Medical to host webcast on 27 May 2019
Sequana Medical announces 2018 Full Year Results and 2019 Outlook
Sequana Medical raises €27.5 million in successful Initial Public Offering
Sequana Medical Announces Publication of Results of Multicentre Randomized Controlled Study
Sequana Medical Announces Results of the MOSAIC trial data presented at 2017 AASLD
Sequana Medical Announces Sudden Passing of Founder, President & CEO
Ian Crosbie Joins Sequana Medical as Chief Financial Officer
Sequana Medical has been selected as a finalist for the 2012 MEDTEC EMDT Innovation Awards
Sequana Medical receives CE Mark Approval for the ALFApumpTM System and adds key executive to team
NovaShunt announces the launch of its new corporate identity: Sequana Medical